Saranya Adukkadukkam

Ms. Saranya Adukkadukkam

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
JMJayaseelan Murugaiyan
Jayaseelan Murugaiyan
APAnand Kumar P
Anand Kumar P
GRG. Srinivasa Rao
G. Srinivasa Rao
Katia ISKANDARKatia ISKANDAR
Katia ISKANDAR
SHStephen Hawser
Stephen Hawser
MDMaarten van Dongen
Maarten van Dongen
Antibiotic resistance, and, in a broader perspective, antimicrobial resistance (AMR), continues to evolve and spread beyond all boundaries. As a result, infectious diseases have become more challenging or even impossible to treat, leading to an increase in morbidity and mortality. Despite the failure of conventional, traditional antimicrobial therapy, in the past two decades, no novel class of antibiotics has been introduced. Consequently, several novel alternative strategies to combat these (multi-) drug-resistant infectious microorganisms have been identified. The purpose of this review is to gather and consider the strategies that are being applied or proposed as potential alternatives to traditional antibiotics. These strategies include combination therapy, techniques that target the enzymes or proteins responsible for antimicrobial resistance, resistant bacteria, drug delivery systems, physicochemical methods, and unconventional techniques, including the CRISPR-Cas system. These alternative strategies may have the potential to change the treatment of multi-drug-resistant pathogens in human clinical settings.

30 January 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Katia ISKANDARKatia ISKANDAR
Katia ISKANDAR
JMJayaseelan Murugaiyan
Jayaseelan Murugaiyan
DHDalal Hammoudi Halat
Dalal Hammoudi Halat
SHSaid El Hage
Said El Hage
VCVindana Chibabhai
Vindana Chibabhai
MDMaarten Van Dongen
Maarten Van Dongen
The history of antimicrobial resistance (AMR) evolution and the diversity of the environmental resistome indicate that AMR is an ancient natural phenomenon. Acquired resistance is a public health concern influenced by the anthropogenic use of antibiotics, leading to the selection of resistant genes. Data show that AMR is spreading globally at different rates, outpacing all efforts to mitigate this crisis. The search for new antibiotic classes is one of the key strategies in the fight against AMR. Since the 1980s, newly marketed antibiotics were either modifications or improvements of known molecules. The World Health Organization (WHO) describes the current pipeline as bleak, and warns about the scarcity of new leads. A quantitative and qualitative analysis of the pre-clinical and clinical pipeline indicates that few antibiotics may reach the market in a few years, predominantly not those that fit the innovative requirements to tackle the challenging spread of AMR. Diversity and innovation are the mainstays to cope with the rapid evolution of AMR. The discovery and development of antibiotics must address resistance to old and novel antibiotics. Here, we review the history and challenges of antibiotics discovery and describe different innovative new leads mechanisms expected to replenish the pipeline, while maintaining a promising possibility to shift the chase and the race between the spread of AMR, preserving antibiotic effectiveness, and meeting innovative leads requirements.

13 March 2026 in APMIS
Verified
Journal Article
Closed access
PDF file
SASaranya Adukkadukkam
Saranya Adukkadukkam
CSChandra Sekhar Suppala
Chandra Sekhar Suppala
KPKarpagavalli Palpandi
Karpagavalli Palpandi
APAnand Kumar P
Anand Kumar P
DLDeepasankari Thulukkapalayam Lingappasamy
Deepasankari Thulukkapalayam Lingappasamy
JMJayaseelan Murugaiyan
Jayaseelan Murugaiyan

Verified
Journal Article
Open access
PDF file
SASaranya Adukkadukkam
Saranya Adukkadukkam
HBHanka Brangsch
Hanka Brangsch
Tamara KozytskaTamara Kozytska
Tamara Kozytska
SKSonika Kar
Sonika Kar
PRPavithra Rajkumar
Pavithra Rajkumar
JMJayaseelan Murugaiyan
Jayaseelan Murugaiyan
Acinetobacter (A.) baumannii is an important multidrug-resistant pathogen increasingly recognized across animal and environmental settings, and carbapenem-resistant A. baumannii (CRAB) is classified as a critical-priority pathogen by the World Health Organization. This study investigated the antimicrobial resistance (AMR) and genomic characteristics of 122 A. baumannii isolates comprising 72 veterinary and 50 environmental isolates collected in Andhra Pradesh, India. Antimicrobial susceptibility testing, whole-genome sequencing (WGS), resistance and virulence gene profiling, multilocus sequence typing (MLST), core-genome analysis, single nucleotide polymorphism (SNP) phylogeny, and pan-genome analysis were performed. Overall, 58.2% of isolates were multidrug-resistant (MDR), and 41.8% were extensively drug-resistant (XDR). Sequence type (ST) 52 predominated among veterinary isolates, whereas ST2 was more frequent among environmental isolates. The presence of carbapenem-resistant isolates along with the ST2 lineage enhances the similarity to clinical A. baumannii. Several intrinsic resistance genes, including blaOXA-23, armA, aph(3″)-Ib, aph(6)-Id, tet(B), mph(E), and msr(E), were more prevalent in the ST2-associated population. Virulence-associated determinants were widely conserved. Core-genome MLST (cgMLST) and core-genome SNP (cgSNP) analyses identified highly related isolates within both lineages, while pairwise SNP differences were 0–7. Pan-genome analysis identified 4204 gene clusters and distinct accessory gene patterns between ST2 and ST52. These findings indicate that resistance gene distribution was closely associated with lineage structure and support integrated genomic surveillance of A. baumannii across animal and environmental reservoirs.